Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Maxim Yankelevich
Barbara Ann Karmanos Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Children'S Hospital of Michigan
Detroit, Michigan, United States
Maxim Y. Yankelevich, MDRecruiting - Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Alexandar Chou, M.D.Shakeel Modak, M.D.Recruiting - University of Virginia, Department of Pediatrics, Hematology/oncology
Charlottesville, Virginia, United States
Daniel (Trey) Lee, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2014
- Primary completion
- 31 Dec 2019
- Completion
- 31 Dec 2019
- Last update posted
- 29 Jan 2019
- Registered enrollment
- 40
- Registry id
- NCT02173093
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.